CDKL5 and craniodiaphyseal dysplasia: The NHS information, combined with other large disease databases [19], has been instrumental in establishing clinical trial readiness through the development of distinct outcome measures [20–23], identifying putative biomarkers [24–26], and supporting clinical trials in CDKL5 deficiency disorder (CDD) [18, 27].